Media type: E-Article Title: Serum adipocyte‐fatty acid binding protein discriminates patients with permanent and temporary body weight loss Contributor: Stejskal, D.; Karpisek, M.; Bronsky, J. Published: Wiley, 2008 Published in: Journal of Clinical Laboratory Analysis, 22 (2008) 5, Seite 380-382 Language: English DOI: 10.1002/jcla.20270 ISSN: 0887-8013; 1098-2825 Origination: Footnote: Description: AbstractAdipocyte‐fatty acid binding protein (A‐FABP) is a biomarker of adiposity and metabolic syndrome. The aim of our work was to investigate the effect of weight reduction on serum A‐FABP value. In the study, we analyzed a group of 189 probands suffering from obesity (102 women and 87 men; aged 57.3±12 years) initially, after a 3‐month low‐fat diet and once again 3 months after the termination of the diet for serum A‐FABP, insulin, glucose, total cholesterol, HDL‐cholesterol, LDL‐cholesterol, and triglycerides. Basal biomarker concentrations were typical of the metabolic syndrome, and moreover A‐FABP correlated with Quicki and BMI. We observed a reduction in BMI in 145 subjects who were divided into two subgroups: A—with persistent BMI reduction even after 6 months, B—with BMI reduction after 3 months and its regress after 6 months. Individuals with rise or no BMI difference were signed as subgroup C. In subgroup A, A‐FABP level increased and returned to the earlier level (42.3 vs 68.3 vs 37.1 µg/l) and correlated with the markers of the metabolic syndrome. In subgroup B, A‐FABP level increased less significantly, however elevated A‐FABP level persisted for 6 months (41.9 vs 53.6 vs 50.7 µg/l). Subgroup C (n=54) showed no difference in A‐FABP after 3‐month diet and after next 3 months. The A‐FABP value correlated with the some components of the metabolic syndrome. In conclusion, we describe that serum A‐FABP might be a prognostic marker of body weight loss suggesting a preventive therapeutic intervention. J. Clin. Lab. Anal. 22:380–382, 2008. © 2008 Wiley‐Liss, Inc. Access State: Open Access